Replimune Group Inc Dossier
Qualitative Analysis
Business overview
Replimune Group, Inc. is a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies designed to transform cancer treatment. The company's proprietary RPx platform is built on a potent, engineered herpes simplex virus 1 (HSV-1) backbone. This platform is designed to maximize immunogenic cell death and induce a systemic anti-tumor immune response through a dual local and systemic mechanism of action. Replimune's lead product candidate is RP1 (vusolimogene oderparepvec), which is being evaluated in combination with checkpoint inhibitors like nivolumab for advanced melanoma and other skin cancers. The pipeline also includes RP2 and RP3, which express additional immune-activating proteins to enhance T-cell responses.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the receipt of a second Complete Response Letter (CRL) from the FDA on April 10, 2026, which deemed the IGNYTE trial data insufficient for accelerated approval, Replimune announced it would halt the development of its lead candidate RP1 in advanced melanoma. The company is implementing job cuts and substantially scaling back its U.S.-based manufacturing operations.
Expected impact: Preservation of cash reserves to extend the company's runway and redirect resources toward the RP2 clinical program.
Shifting strategic focus to RP2, an oncolytic immunotherapy engineered to express an anti-CTLA-4 antibody. Key trials include the registration-directed Phase 2/3 REVEAL study in metastatic uveal melanoma (evaluating RP2 + nivolumab vs. ipilimumab + nivolumab) and liver-focused Phase 2 studies in hepatocellular carcinoma and biliary tract cancer.
Expected impact: Establishment of a new lead clinical asset with potential accelerated approval pathways in difficult-to-treat cancers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Roche supplies atezolizumab and bevacizumab for use in combination with RP2 in Replimune's Phase 2 clinical trial for anti-PD-1/PD-L1 progressed hepatocellular carcinoma.
Terms: Roche provides the therapeutic compounds at no cost; Replimune sponsors and funds the clinical trial.
BMS provides nivolumab (Opdivo) at no cost for evaluation in combination with RP2 in the registration-directed Phase 2/3 REVEAL study in metastatic uveal melanoma.
Terms: BMS provides the compound at no cost; Replimune sponsors, conducts, and funds the clinical trial.